Cytokinetics, Incorporated
CYTK
Rank in Stocks
#2308
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Share Price
$62.08
Market Cap
$8.63B
Change (1 day)
0.21%
Change (1 year)
6.23%
Country
US
Trade Cytokinetics, Incorporated (CYTK)
Category
Healthcare
P/E ratio for Cytokinetics, Incorporated (CYTK)
P/E ratio as of October 2026 TTM: -8.80
According to Cytokinetics, Incorporated latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.80. At the end of 2023 the company had a P/E ratio of -15.31.
P/E ratio history for Cytokinetics, Incorporated from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -8.80 | -1.59% |
| 2024 | -8.94 | -41.65% |
| 2023 | -15.31 | 44.72% |
| 2022 | -10.58 | -34.99% |
| 2021 | -16.28 | 54.52% |
| 2020 | -10.53 | 109.84% |
| 2019 | -5.02 | 55.13% |
| 2018 | -3.24 | 2.70% |
| 2017 | -3.15 | -110.68% |
| 2016 | 29.50 | -373.53% |
| 2015 | -10.78 | -44.78% |
| 2014 | -19.53 | 271.42% |
| 2013 | -5.26 | 205.61% |
| 2012 | -1.72 | 21.15% |
| 2011 | -1.42 | -47.81% |
| 2010 | -2.72 | -139.99% |
| 2009 | 6.80 | -372.50% |
| 2008 | -2.50 | -45.76% |
| 2007 | -4.60 | -4.00% |
| 2006 | -4.80 | 8.73% |
| 2005 | -4.41 | -19.07% |
| 2004 | -5.45 | 479.01% |
| 2003 | -0.94 | -22.54% |
| 2002 | -1.22 | -15.62% |
| 2001 | -1.44 | 21.20% |
| 2000 | -1.19 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -427.16% |
US
|
|
| -28.36 | 222.35% |
US
|
|
| -24.57 | 179.25% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -444.76% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.